These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2455817)

  • 1. Separate epitopes in the envelope of visna virus are responsible for fusion and neutralization: biological implications for anti-fusion antibodies in limiting virus replication.
    Crane SE; Clements JE; Narayan O
    J Virol; 1988 Aug; 62(8):2680-5. PubMed ID: 2455817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing and fusion-blocking antibodies induced by recombinant visna virus envelope glycoprotein.
    Huso DL
    Viral Immunol; 1997; 10(1):15-20. PubMed ID: 9095528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of the fusion domain in the visna virus transmembrane protein.
    Crane SE; Kanda P; Clements JE
    Virology; 1991 Nov; 185(1):488-92. PubMed ID: 1656602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographical rearrangements of visna virus envelope glycoprotein during antigenic drift.
    Stanley J; Bhaduri LM; Narayan O; Clements JE
    J Virol; 1987 Apr; 61(4):1019-28. PubMed ID: 2434662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of a principal neutralization domain of visna/maedi virus envelope glycoprotein.
    Haflidadóttir BS; Matthíasdóttir S; Agnarsdóttir G; Torsteinsdóttir S; Pétursson G; Andrésson ÓS; Andrésdóttir V
    J Gen Virol; 2008 Mar; 89(Pt 3):716-721. PubMed ID: 18272763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of recombinant gp135 to study epitope-specific antibody responses to maedi visna virus.
    Carey N; Roy DJ; Dalziel RG
    J Virol Methods; 1993 Jul; 43(2):221-32. PubMed ID: 7690044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of transgenic sheep that express the visna virus envelope gene.
    Clements JE; Wall RJ; Narayan O; Hauer D; Schoborg R; Sheffer D; Powell A; Carruth LM; Zink MC; Rexroad CE
    Virology; 1994 May; 200(2):370-80. PubMed ID: 8178428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maedi-visna virus persistence: Antigenic variation and latency.
    Arnarson H; Pálsson A; Gudnadóttir M; Andrésdóttir V
    Comp Immunol Microbiol Infect Dis; 2017 Dec; 55():6-12. PubMed ID: 29127994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.
    Widjaja I; Wicht O; Luytjes W; Leenhouts K; Rottier PJM; van Kuppeveld FJM; Haijema BJ; de Haan CAM
    J Virol; 2016 Jul; 90(13):5965-5977. PubMed ID: 27099320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope mapping of human immunodeficiency virus: a monoclonal approach.
    Folks TM
    J Immunol; 1987 Dec; 139(12):3913-4. PubMed ID: 2447155
    [No Abstract]   [Full Text] [Related]  

  • 11. Domains of herpes simplex virus I glycoprotein B that function in virus penetration, cell-to-cell spread, and cell fusion.
    Navarro D; Paz P; Pereira L
    Virology; 1992 Jan; 186(1):99-112. PubMed ID: 1370130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a maedi-visna virus CA-TM fusion protein ELISA with other assays for detecting sheep infected with North American ovine lentivirus strains.
    DeMartini JC; Halsey W; Boshoff C; York D; Howell MD
    Vet Immunol Immunopathol; 1999 Oct; 71(1):29-40. PubMed ID: 10522784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus.
    Narayan O; Clements JE; Griffin DE; Wolinsky JS
    Infect Immun; 1981 Jun; 32(3):1045-50. PubMed ID: 6166562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutralizing antibody responses and evolution of antigenic variants in monozygotic twin lambs infected with phenotypically distinct ovine lentiviruses.
    Cheevers WP; Cordery-Cotter R; McGuire TC; DeMartini JC
    Virology; 1999 Jun; 258(2):382-8. PubMed ID: 10366575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naturally occurring mutations within 39 amino acids in the envelope glycoprotein of maedi-visna virus alter the neutralization phenotype.
    Skraban R; Matthíasdóttir S; Torsteinsdóttir S; Agnarsdóttir G; Gudmundsson B; Georgsson G; Meloen RH; Andrésson OS; Staskus KA; Thormar H; Andrésdóttir V
    J Virol; 1999 Oct; 73(10):8064-72. PubMed ID: 10482555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mapping and characterization of visna/maedi virus cytotoxic T-lymphocyte epitopes.
    Wu C; Barbezange C; McConnell I; Blacklaws BA
    J Gen Virol; 2008 Oct; 89(Pt 10):2586-2596. PubMed ID: 18796728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antigenic variation of neutralization-sensitive epitopes of caprine arthritis-encephalitis lentivirus during persistent arthritis.
    McGuire TC; Norton LK; O'Rourke KI; Cheevers WP
    J Virol; 1988 Sep; 62(9):3488-92. PubMed ID: 2457116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antigenic and functional organization of human parainfluenza virus type 3 fusion glycoprotein.
    van Wyke Coelingh K; Tierney EL
    J Virol; 1989 Jan; 63(1):375-82. PubMed ID: 2462062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing antibodies to visna lentivirus: mechanism of action and possible role in virus persistence.
    Kennedy-Stoskopf S; Narayan O
    J Virol; 1986 Jul; 59(1):37-44. PubMed ID: 3012120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigenic variation during persistent lentivirus infections and its implications for vaccine development.
    Montelaro R; Ball J; Rwambo P; Issel C
    Adv Exp Med Biol; 1989; 251():251-72. PubMed ID: 2481964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.